Jefferies raises Regeneron stock price target to $930 on partnership

Jefferies raised Regeneron’s price target to $930 from $870 and reiterated Buy, implying more than 25% upside from the approximately $740 share price, following the expansion of its Sanofi alliance. Regeneron will receive $1 billion upfront and may earn up to $7 billion in milestones while splitting global development costs and profits 50/50 for four next-generation type-2 inflammation assets. Jefferies estimates potential sales of roughly $3 billion for REGN20423 and $1 billion for an IL-4xIL-13 bispecific, though both estimates incorporate early-stage probabilities of success.

Analysis

The economic reset improves REGN’s long-duration immunology value more than near-term earnings: the upfront payment is modest relative to its cash generation, while equal ex-U.S. profit participation raises the value of successful assets versus the legacy geographic split. The key underwriting issue is not headline peak sales but whether the new mechanisms can earn meaningful share from Dupixent rather than merely extend the franchise; if so, REGN captures a higher proportion of lifecycle-management economics without bearing incremental commercial infrastructure costs.

The agreement also makes SNY a cleaner near-term operating beneficiary than the market may recognize. SNY retains access to REGN’s discovery engine while sharing development risk on a portfolio that could defend its immunology franchise against IL-13 competitors and future biosimilar pressure. Conversely, the relevant competitive risk sits with Amgen (AMGN), LEO Pharma’s privately held dermatology franchise, and smaller inflammation-platform biotechs: a credible next-generation class could raise required trial spend and reduce terminal-value assumptions across atopic dermatitis and asthma pipelines.

Near-term upside in REGN should be constrained by the early-stage nature of the assets; probability-weighted pipeline value is highly sensitive to trial design, differentiation versus existing biologics, and launch timing. Over the next 1-3 months, the catalyst is management disclosure on development sequencing, cost-sharing expense, and whether the upfront payment is recognized in collaboration revenue. Over 6-18 months, proof of mechanistic differentiation—durability, dosing convenience, and efficacy in patients inadequately controlled by Dupixent—is the only catalyst likely to support durable multiple expansion.

Consensus may over-credit the analyst target revisions while under-crediting the strategic signal: a partner with global scale accepting 50/50 economics suggests confidence in the platform, but it does not establish commercial superiority. The thesis is falsified if R&D guidance rises materially without offsetting collaboration income, if pipeline prioritization delays pivotal programs, or if new-asset data fail to show a clinically relevant advantage over standard IL-4Rα blockade.

Key Decisions for Investors

• Accumulate REGN on weakness rather than chase a target-price-driven move; use a 6-18 month horizon and size to a pipeline-risk budget. Base case is modest multiple expansion from higher ex-U.S. economics, with upside dependent on differentiation data rather than the upfront payment.
• Express relative value via long REGN / short AMGN in equal beta-adjusted dollars over 6-12 months, conditional on REGN maintaining R&D guidance. REGN gains strategic immunology optionality, while AMGN faces a higher bar for inflammatory-disease pipeline differentiation; exit if REGN’s incremental R&D burden exceeds collaboration support or early data are inconclusive.
• Maintain SNY as the lower-volatility way to participate in the alliance, but do not add solely on this development. Reassess at the next earnings call for disclosure of development-cost cadence and any revised immunology margin outlook; absent that, the financial contribution is too back-end loaded for a standalone catalyst trade.
• Set an event watch on REGN clinical-program timelines and trial endpoints. Consider adding only after confirmation that at least one lead asset targets less-frequent dosing, superior response durability, or Dupixent-inadequate responders; without that differentiation, the portfolio risks value transfer through internal cannibalization rather than net franchise expansion.